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The human immunodeficiency virus type 1 exterior gp120 envelope glycoprotein is highly flexible, and this
flexibility may contribute to the inability of monomeric gp120 immunogens to elicit broadly neutralizing antibodies.
We previously showed that an S375W modification of a critical interfacial cavity central to the primary receptor
binding site, the Phe43 cavity, stabilizes gp120 into the CD4-bound state. However, the immunological effects of this
cavity-altering replacement were never tested. Subsequently, we screened other mutations that, along with the
S375W alteration, might further stabilize the CD4-bound state. Here, we define a selected second cavity-altering
replacement, T257S, and analyze the double mutations in several gp120 envelope glycoprotein contexts. The gp120
glycoproteins with the T257S-plus-S375W double mutation (T257SS375W) have a superior antigenic profile
compared to the originally identified single S375W replacement in terms of enhanced recognition by the broadly
neutralizing CD4 binding-site antibody b12. Isothermal titration calorimetry measuring the entropy of the gp120
interaction with CD4 indicated that the double mutant was also stabilized into the CD4-bound state, with increasing
relative fixation between core, full-length monomeric, and full-length trimeric versions of gp120. A significant
increase in gp120 affinity for CD4 was also observed for the cavity-filling mutants relative to wild-type gp120. The
most conformationally constrained T257SS375W trimeric gp120 proteins were selected for immunogenicity
analysis in rabbits and displayed a trend of improvement relative to their wild-type counterparts in terms of eliciting
neutralizing antibodies. Together, the results suggest that conformational stabilization may improve the ability of
gp120 to elicit neutralizing antibodies.
The human immunodeficiency virus type 1 (HIV-1) envelope
glycoproteins gp120 and gp41 form a specialized type I viral mem-
brane fusion complex that mediates viral entry (9). The gp120
glycoprotein is composed of two major structural domains which
contribute to the receptor-binding elements that interact with the
viral receptors CD4 and CCR5/CXCR4 (1, 8, 11, 13, 14, 16).
HIV-1 gp41 contains the trimerization domain and mediates vi-
ral-to-target-cell membrane fusion (17). Because the trimeric gly-
coprotein spike mediates receptor binding and is the only viral
gene product on the surface of HIV, it is the sole target for
virus-specific neutralizing antibodies. Attempts to elicit broadly
neutralizing antibodies using monomeric gp120 (2, 3, 4, 10, 26,
44), peptide regions from gp41 (27, 31, 36), or trimeric soluble
gp140 mimics of the envelope spike (15, 19, 24, 38, 48) were met
with limited success. Therefore, we sought novel and alternative
means to achieve this goal.
We suggested previously that the extreme flexibility of gp120
may present many conformations to the humoral immune sys-
tem not found on the functional spike and may contribute to its
tendency to elicit antibodies that bind to monomeric gp120 but
rarely broadly neutralizing antibodies (30, 47). Broadly neu-
tralizing antibodies presumably bind relatively efficiently to
conserved regions of the functional spike that are shrouded by
glycan and immunodominant variable elements, hence render-
ing them poorly immunogenic. Binding antibodies, specifically
those that can bind to conserved gp120 elements but not the
functional spike, recognize “open” conformations of gp120
that are not accommodated on the spike due to conformational
masking (21) or nonneutralizing determinants involved in tri-
mer contacts. Hence, neither of these types of epitopes is
exposed on the assembled, constrained quaternary structure of
the functional spike. Therefore, as an avenue of immunogen
development, we sought means to lock gp120 into a con-
strained conformation that is known to exist on the functional
spike. One such conformation, highly relevant to the entry
process, which needs to be sampled by the functional spike for
entry and fusion, is the CD4-bound conformation of gp120.
Normally, CD4 is required to induce this conformation (22,
30). Here, we have extended our attempts to generate the CD4
state of gp120 by a mutagenic approach as described previously
(47). Guided by the X-ray crystal structure of the ternary
complex of gp120, CD4, and the chemokine receptor mimetic
antibody 17b, we demonstrated that a single serine (S)-to-
tryptophan (W) replacement of amino acid 375 in a region
described as the “Phe43 cavity” significantly stabilized gp120
into the CD4-bound conformation (22, 47). The Phe43 cavity
lies at the nexus of the gp120 inner domain, outer domain, and
bridging sheet and is proximal to critical contacts with the
primary receptor, CD4. Besides restricting the conformational
flexibility of gp120, the cavity-filling mutation increases CD4
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and 17b recognition slightly while eliminating recognition by
several nonneutralizing CD4 binding-site-directed (CD4BS)
antibodies. Conversely, other mutations in the bridging sheet
could eliminate recognition by CD4 while retaining recogni-
tion by the CD4BS antibodies. These data suggested a model
by which the cavity mutation locked gp120 in a conformation
favorable for CD4 and 17b recognition (and hence CCR5
interaction and entry) but not for recognition by the nonneu-
tralizing CD4BS antibodies (47). Hence, we termed the cavity-
filled gp120 proteins to be in the “CD4 state” even though
entropy analysis indicated that the conformational alteration,
although substantial, was not absolute. To further lock gp120
into the CD4-17b-bound conformation, or CD4 state, we an-
alyzed a set of second-site mutations based upon the following
criteria. The first subset was designed to relieve a potential
clash of the bulky 375W residue with residue T257 in the Phe43
cavity. The second subset of noncavity mutations were intro-
duced since they, by themselves, cause decreases in recognition
by the CD4BS antibodies without affecting CD4 recognition
greatly as previously reported (40, 41, 42). Since 17b and CD4
recognize the same conformation of gp120 and since CD4
induces high-affinity binding of gp120 to CCR5, we ranked the
double mutants based upon 17b and CCR5 recognition in the
absence of CD4. From these data and technical issues of pro-
tein solubility following deglycosylation, we selected a second
cavity-altering mutation, T257S, in combination with the
S375W change (T257SS375W), for further antigenic and bio-
physical analyses. Several gp120 contexts were tested to deter-
mine the best candidate to analyze the impact of the cavity-
filling, CD4-state mutations on the elicitation of neutralizing
antibodies.
As previously reported, although the S375W mutation elim-
inated the recognition of gp120 by several nonneutralizing
CD4BS antibodies, it also adversely affected recognition by the
broadly neutralizing CD4BS antibody b12 (47). Due to the
neutralization breadth and potency of the b12 antibody, we
reasoned that it is likely desirable to retain the b12 epitope in
a gp120-based immunogen design (6). Somewhat fortuitously,
when the T257S replacement was introduced along with the
S375W CD4-state mutation, b12 recognition was increased,
while protein stabilization was maintained.
Given this improved protein design, we sought to test the hy-
pothesis that the stabilization of gp120 in the CD4-bound confor-
mation would provide an immunological benefit in eliciting
broadly cross-reactive neutralizing antibodies. In this study, we
report the antigenic, biochemical, and biophysical characteriza-
tion of cavity-altered double mutant proteins in monomeric con-
texts (core and full-length gp120) and in the recently character-
ized trimeric gp120-GCN4 context (32). Because the cavity
alterations had the greatest degree of stabilization in the trimeric
gp120 context, we assessed the ability of the stabilized soluble
gp120 spike mimetics to elicit neutralizing antibodies relative to
wild-type (WT) monomeric and trimeric gp120 glycoproteins.
MATERIALS AND METHODS
Cells and proteins. HEK293 cells were obtained from the American Type
Culture Collection. Soluble human D1D2 CD4 was obtained through the NIH
AIDS Reference and Reagent Program, Division of AIDS, NIAID, NIH (18).
The monoclonal antibodies b12 and b6 used in this study were engineered as
immunoglobulin G1 constructs as previously described (6) and were generous
gifts from Dennis Burton, and F105 (34, 35) was kindly provided by Marshal
Posner. 2G12 (43) and 2F5 (29) were kind gifts from Herman Katinger. The 17b
antibody (41) and the biotinylated guinea pig IgG anti-CD4 were kindly provided
by James Robinson.
Construction of Env expression plasmids. The unmodified YU2 core expres-
sion plasmid pBD103 was derived from a previously described YU2
gp120V1V2V3-GCN4 construct (32) by the deletion of the N terminus (amino
acids 1 to 81) and the C terminus (amino acid 497 onward) and by the intro-
duction of a stop codon upstream of the GCN4 trimerization sequence. The
mutant core protein with Phe43 cavity-filling mutations was expressed from
plasmid pBD105 by altering two amino acid residues at positions 375 (from
serine to tryptophan) and 257 (from threonine to serine) in pBD103. As previ-
ously described, monomeric and trimeric WT gp120 proteins were expressed
from plasmids encoding WT YU2 gp120 monomers and YU2 gp120-GCN4
trimers, respectively (32). Codon changes to introduce S375W and T257S mu-
tations into the YU2 gp120 monomeric WT and YU2 gp120-GCN4 plasmids for
expressing monomeric and trimeric mutant gp120 proteins then generated plas-
mids pBD202M and pBD202T, respectively. Generation of the cysteine-con-
strained HXBc2 core Ds12F123 construct was described elsewhere previously
(49). All the above-mentioned modifications were made by QuikChange mu-
tagenesis (Stratagene) in pcDNA3.1-based constructs and confirmed by sequenc-
ing. Site-directed mutagenesis was also used to introduce second-site replace-
ments into the previously described YU2 375S/W protein containing deletions of
N-terminal gp120 residues 31 to 81 and V1/V2 residues 128 to 194 (47). For
making WT pseudotyped YU2 virus, the open reading frame of the YU2 gp160
protein was inserted into KpnI and BamHI sites of vector pSVIIIenv to generate
an Env expressor plasmid (39). Site-directed mutagenesis was performed to
introduce an S375W and/or a T257S mutation to generate the mutant Env
expressor plasmids. In all cases, the numbering of gp120 amino acid residues is
based on the sequence of the prototypic HXBc2 strain (20).
Molecular modeling. Designing an S375W mutation in the context of a trun-
cated YU2 gp120 protein was described previously (47). The modeling suggested
a potential clash between the bulky tryptophan side chain and the C-gamma
atom of threonine 257 that might have an impact on core gp120 protein stability.
Therefore, a second mutation changing threonine to serine at position 257 was
designed to alleviate the potential clash. The mutation was introduced into core
gp120, full-length monomeric gp120, and full-length trimeric gp120 molecules.
The rationale for modeling other second-site replacements to enhance the CD4-
bound conformation is found in Table 1.
Expression and purification of monomeric and trimeric envelope glycopro-
teins. All proteins were expressed in serum-free medium by transient transfec-
tion of HEK293T cells. Briefly, HEK293T cells growing in Dulbecco’s modified
Eagle’s medium plus 10% fetal bovine serum, 2 mM glutamine, and 1 peni-
cillin-streptomycin (50 units/ml penicillin, 50 g/ml streptomycin) were seeded at
a density of 1.2  107 cells per 150-cm2 tissue culture dish. After overnight
incubation, cells were transfected with a mixture of expressor plasmid and the
transfection reagent Fugene (Roche) according to the manufacturer’s instruc-
tions. The following day, transfection medium was replaced with 293 SFMII
(serum-free medium) supplemented with 4 mM glutamine. Four days later,
culture supernatants were collected, centrifuged at 3,500  g to remove cell
debris, filtered through sterile 0.2-m filters, and stored at 4°C (for a maximum
of up to 2 weeks) in the presence of protease inhibitors prior to purification. All
proteins were purified over affinity columns, and in selected cases, the trimeric
fractions were isolated by size exclusion chromatography. The F105 (34, 35)
affinity column was used for the purification of unmodified core and WT gp120
trimer proteins. Either an F105 or a b12 (6) affinity column was used for WT
gp120 monomer protein purification, and a 17b (41) affinity column was used to
purify all mutant proteins. For purification of monomeric proteins, the culture
supernatant was applied to the affinity column overnight at room temperature
(RT), and the column was washed with 10 volumes of phosphate-buffered saline
(PBS) (pH 7.4) containing 0.5 M NaCl and washed with 5 volumes of PBS
containing 0.15 M NaCl, eluted with 100 mM glycine (pH 2.8), and the eluate was
immediately neutralized to pH 7.0 with 1 M Tris base. Trimeric proteins were
eluted with 3 M MgCl2 prepared in 20 mM Tris-HCl (pH 7.4). For all proteins,
eluted fractions containing proteins, as determined by the optical density (OD)
at 280 nm, were pooled, concentrated with Amicon Ultra centrifugal filter de-
vices (Millipore, Bedford, MA), and dialyzed extensively against PBS (pH 7.4).
Protein aliquots were flash-frozen in liquid nitrogen and stored at 80°C until
further use.
Affinity-purified trimeric proteins were further subjected to size exclusion
chromatography using a Superdex 200 16/26 column (Amersham Pharmacia) in
PBS containing 0.35 M NaCl. The flow rate was set to 1 ml/min for the first 100
min and reduced to 0.5 ml/min until the end of the run, which allowed the
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separation of the oligomeric species. Relevant fractions were pooled, concen-
trated, dialyzed against PBS (pH 7.4), flash-frozen, and stored at 80°C.
Native gel analysis. Before and after size exclusion chromatography, mono-
meric and trimeric gp120 proteins were run on blue native gels to analyze the
purity of the oligomeric states. The running buffer for the outer chamber con-
tained 50 mM Tris-HCl plus 50 mM MOPS (morpholinepropanesulfonic acid)
(pH 7.7). The inner chamber buffer also contained 0.001% of SERVA Blue G
(catalog no. 35050). Protein samples were diluted 1:1 in 2 sample buffer (100
mM Tris-HCl, 100 mM MOPS, 40% glycerol, 0.1% Serva-Blue G [pH 7.7]) and
run for 4 h at 4°C at 100 mV. Standard molecular weight markers were included
in the analysis. Following electrophoresis, gels were stained with Coomassie blue
and then destained according to standard procedures used for sodium dodecyl
sulfate (SDS)-containing gels.
Immunoprecipitation. CD4 induction of gp120 proteins for 17b binding was
measured by immunoprecipitation assays as follows. In separate microcentrifuge
tubes, 1 ml of culture supernatant was incubated without or with 10 g of soluble
CD4 (sCD4) (human D1D2) for 30 min at RT. Ten micrograms of 17b and 25 l
of a 50% suspension of Sepharose-protein A beads were then added to each
reaction mixture and incubated for 1 h at RT. The beads were then pelleted by
centrifugation at 5,000 rpm for 2 min and washed twice with PBS (pH 7.4)
containing 0.5 M NaCl and twice with PBS (pH 7.4). Each pellet was then
resuspended in 30 l of reducing SDS sample buffer and heated to 100°C for 5
min. The contents were mixed by vortexing and centrifuged at 10,000 rpm for 2
min to pellet the beads. The supernatant fractions were then carefully subjected
to SDS-polyacrylamide gel electrophoresis (PAGE) and Coomassie staining us-
ing standard procedures.
ELISA. The antigenicities of WT and mutant envelope proteins were deter-
mined by standard a enzyme-linked immunosorbent assay (ELISA) as follows.
Corning high-protein-binding ELISA plates were coated with 400 ng per well of
Galanthus nivalis lectin (catalog no. L8275-5MG; Sigma) in 100 l of PBS (pH
7.4) at 4°C overnight. The lectin was then removed, and the wells were blocked
for 3 h at RT with PBS–2% fat-free milk and 4% fetal calf serum, followed by five
washes with wash buffer (PBS–0.2% Tween 20). The wells were then incubated
with 200 ng of protein in 100 l of PBS for 2 h at RT, followed by five washes and
incubation with 100 l of different anti-gp120 monoclonal antibody solutions that
were fivefold serially diluted starting with 20 g/ml of the initial concentration in
dilution buffer (1:10-diluted blocking buffer). Following 1 h of incubation at RT,
the wells were washed and incubated for 1 h at RT with 100 l of a horseradish
peroxidase (HRP)-conjugated anti-human IgG (catalog no. 109-036-097; Jack-
son ImmunoResearch Laboratories, Inc.) solution at a 1:10,000 dilution in an-
tibody dilution buffer. After five washes, 100 l of the colorimetric peroxide
enzyme immunoassay substrate (3,3,5,5-tetramethylbenzidine; Bio-Rad) was
added to each well, and the reaction was stopped by adding 100 l of 1 M sulfuric
acid to the mixture. The OD of the wells was read at 450 nm using an ELISA
plate reader. All samples were run in duplicates. The average OD of negative
control wells containing bovine serum albumin (BSA) was subtracted from the
average OD of experimental wells to obtain the final OD values. For the ELISA
of unmodified and mutant YU2 core proteins shown in Fig. 1B (left panels) and
for the analyses described in the legend of Fig. 8, 200 ng of proteins was directly
coated onto each well of the ELISA plates.
To determine the anti-gp120 antibody titers in immunized sera (see Table 3),
ELISA plates were coated with 200 ng of WT YU2 gp120 monomeric protein in
100 l of PBS per well. After blocking and washes, fivefold serial dilutions
(starting at 1/200) of the sera from immunized rabbits were added in duplicate
wells and incubated for 2 h at RT. Following washes, the wells were incubated
with a 1:10,000 dilution of HRP-conjugated anti-rabbit IgG (catalog no. 111-
035-046; Jackson ImmunoResearch Laboratories, Inc.) and developed with HRP
substrate, and the ODs were read at 450 nm.
For characterizing the binding properties of antibodies elicited by the three
different immunogens used in this study (as shown in Fig. 7), ELISA plates were
coated with 100 l of unmodified core protein (2 g/ml) and incubated with
fivefold serial dilutions (starting at 1/200) of the immune sera (following four
inoculations at a 125-g dosage) in 100 l of 1:5-diluted blocking buffer. After 30
min at RT, 100 l of D1D2 CD4 (0.8 g/ml in 1:5-diluted blocking buffer) was
added to each plate for 1 h at RT. The plates were then washed and incubated
with a 1:2,500 dilution of biotinylated guinea pig IgG anti-CD4 for 1 h at RT.
Following washes, the wells were incubated with 100 l of a 1:200 dilution of
streptavidin-peroxidase (S2438; Sigma) and developed with HRP substrate, and
the ODs were read at 450 nm.
ITC. Isothermal titration calorimetry (ITC) was carried out using a VP-ITC
titration calorimeter system from MicroCal, Inc. All proteins, including sCD4
(D1D2), were thoroughly dialyzed against PBS and degassed before use. The
dialysis buffer was filtered through a 0.2-m membrane and used to dilute the
protein samples. The concentration of envelope protein in the sample cell was
approximately 4 M, and the concentration of sCD4 in the syringe was approx-
imately 40 M. The reference cell contained degassed Milli-Q water. Envelope
glycoproteins in the sample cell were titrated to saturation by the stepwise
addition of 10 l of sCD4 from the syringe at 400-s intervals at 37°C. The heat
evolved upon each injection of titrant (sCD4) was obtained from the integral of
the calorimetric signal. The heat of dilution of sCD4 was subtracted from the
heat of reaction with gp120 to obtain the heat associated with the binding
reaction. The molar concentrations of the proteins were calculated using the
following molar extinction coefficients: core, 1.22; mutant core, 1.38; WT gp120,
1.41; mutant gp120, 1.52; WT trimer, 1.4; mutant trimer, 1.38. The specific
activity of sCD4 was determined to be approximately 80% as described previ-
ously (32). The values for enthalpy (H), entropy (S), and the association
constant (Ka) were obtained by fitting the data to a nonlinear least-squares
analysis with Origin software.
Immunization protocol. New Zealand White rabbits (females, approximately
12 weeks of age) were inoculated by the intradermal route with 125 g of
proteins emulsified in a 1:1 dilution of Ribi adjuvant (Corixa, Hamilton, MT) in
a total volume of 1 ml. One inoculation of 500 l each was administered in each
hind leg. The protein-adjuvant emulsions were prepared within 2 h of inoculation
into animals. Boosting inoculations were administered at 4-week intervals fol-
TABLE 1. Second-site mutants in combination with the 375S/W CD4-state mutationa
gp120
positionb
Introduced
change Description
Relative bindingc
17b CCR5
None 1.0 1.0
257 T/A Removes potential steric clash with Trp375 0.8 0.5
T/M Should exacerbate steric clash with Trp375 0.3 0.3
T/S Removes steric clash while maintaining important side chain hydroxyl
H bond at position 257
1.1 1.1
266 A/E Reduces binding for CD4BS antibodies 15e, 21h, and 1125h 1.15 0.7
386 N/Q Decreased recognition of CD4BS antibodies 15e, 21h, and 1125h 0.85 0.9
429 E/F Enhances overall hydrophobic stability of the bridging sheet 0.85 0.5
435 Y/W Enhances hydrophobic interactions between the bridging sheet and
Phe382 of the outer domain
0.55 0.00
470 P/G Decreased CD4BS antibody recognition while maintaining CD4 binding 0.4 0.4
a The rationale was to lock gp120 into the conformation recognized by CD4 and 17b, a 375S/W replacement in the gp120 Phe43 cavity that increased the binding
affinity of gp120 to CD4 and reduced binding to several CD4BS antibodies (47). The mutation also increased binding to CD4i antibody 17b and to the chemokine
receptor CCR5, which was used here to select the T257S mutant for further analysis.
b Second-site mutations were incorporated into the previously described 375S/W gp120 protein (47).
c Radiolabeled soluble envelope glycoproteins were produced by transient transfection of 293T cells and analyzed for recognition by multiple ligands in immuno-
precipitation assays as described previously (47). The amount of precipitated mutant protein relative to that of the WT protein was determined by PhosphorImager
analysis (Molecular Dynamics) and converted to a relative scale where YU2 375S/W recognition by 17b and CCR5 in the absence of CD4 was equal to 1.00.
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lowing the initial inoculation. Test bleeds were collected 7 to 10 days after each
booster inoculation. For serum preparation, blood was incubated at RT for 2 h
to allow clotting and centrifuged for 10 min at 2,000  g to separate the liquid
phase from the clotted components. The serum was heat inactivated at 56°C for
1 h and stored at 20°C for subsequent analysis.
Neutralization assays. HIV-1 was pseudotyped with selected envelope glyco-
proteins by the cotransfection of an env expressor and viral genomic DNA with
a deletion of Env into 293T cells. Following the production of pseudotyped virus,
a luciferase-based neutralization assay was performed as previously described
(24). Briefly, TZM-bl cells expressing CD4, CXCR4, and CCR5 were used for
HIV-1 infection. These target cells contain Tat-responsive reporter genes for
firefly luciferase and the Escherichia coli -galactosidase gene under the regula-
tory control of the HIV-1 long terminal repeat. The level of HIV-1 infection was
quantified by measuring relative light units (RLU) of luminescence, which is
directly proportional to the amount of virus input. The assays were performed
using a 96-well microtiter plate format with 10,000 TZM-bl cells per well. The
construction and preparation of pseudotyped viruses were described elsewhere
previously (23). For neutralization assays, each pseudotyped virus stock was
diluted to a level that produced approximately 100,000 to 500,000 RLU. The
percentage of virus neutralization by each immune serum sample was derived by
calculating the reduction in RLUs in the test wells compared to the RLUs in the
wells containing preimmune serum from the corresponding animal. To control
for nonspecific neutralization in protein-immunized rabbits, sera from two ani-
mals immunized with BSA were analyzed. All serum samples were also assayed
for neutralizing activity against a pseudovirus expressing the amphotropic murine
leukemia virus envelope to test for non-HIV-1-specific plasma effects (25).
Neutralization of HIV-2 strain 7312A/V434M was performed as previously
described (12). Briefly, pseudovirus stock was treated with mock media or with
0.5 g/ml of sCD4 (50% inhibitory concentration [IC50] for entry of this virus)
for 1 h before adding sera. The remainder of the assay was done as described
above. To calculate the percent neutralization with sCD4 present in the assay,
the baseline RLU was the value measured with virus plus sCD4 and no serum.
To obtain IC50 data, fivefold serial dilutions of immune sera were incubated
with viruses before infection of target cells. Antiserum dose-response curves
were fit with a nonlinear function, and the IC50 for the corresponding virus was
calculated by a least-squares regression analysis. Statistical analysis of the IC50
titers was performed with the unpaired t test (GraphPad Prism software package
3.0; GraphPad Software Inc., San Diego, CA).
Virus entry assay. WT and mutant pseudotyped YU2 viruses were produced
by cotransfection of envelope glycoprotein expressor plasmids and viral genomic
DNA with a deletion of the env gene into 293T cells. Pseudovirus titers were
adjusted by p24 ELISA (Beckman Coulter) according to the manufacturer’s
protocol. Equivalent doses of virus suspended in a 40-l volume were then mixed
with 20 l of TZM-bl cells (10,000 cells) and 10 l of medium on 96-well plates
and incubated overnight at 37°C. The following day, 130 l of cell culture
medium was added to each well and incubated for an additional 24 h. Cell culture
medium then was removed from all wells, and 50 l of cell lysis buffer (Promega,
Madison, WI) was added. Thirty microliters of cell lysis supernatant was trans-
ferred onto a new plate containing substrate for the measurement of lumines-
cence using a luminometer. The RLU produced by the wells were measured and
used to calculate viral entry. To determine antibody-mediated neutralization of
HIV-1 entry, each viral inoculum was preincubated with fourfold serial dilutions
of antibody in 50 l of medium for 1 h at 37°C. After virus-antibody incubation,
the TZM-bl target cells were added to all wells. The initial concentrations of the
antibodies tested were as follows: b12, 25 g/ml (6); 2F5, 50 g/ml (29); and HIV
IgG (IgG pool from HIV-infected patient sera), 5 mg/ml.
IgG adsorption and elution assay. Equal volumes (150 l) of rabbit sera were
mixed separately with recombinant protein A-conjugated Sepharose Fast Flow
beads (catalog no. 17-1279-02; Amersham) and unconjugated Sepharose 4B
beads (catalog no. 4B200; Sigma) at a 1:1 ratio of serum to beads in microcen-
trifuge tubes and incubated for 1 h at RT with continuous mixing in a nutating
mixer. The adsorbed sera were then separated by pelleting the beads for 3 min
at 5,000  g. The beads were washed twice with 1.2 ml PBS containing 0.5 M
NaCl and once with PBS (0.15 M NaCl), and all liquid was removed from the top
of the pellets. In order to elute captured IgG from the beads, each pellet was
resuspended in 135 l of 0.1 M glycine (pH 2.0) for 1 min at RT and then
centrifuged at 500  g for 3 min. The supernatant containing IgG was then
separated, and the pH was neutralized by adding 15 l of 1 M Tris (pH 8.5). The
percent recovery of IgG was determined by ELISA, where fivefold serial dilu-
tions of untreated sera as well as different fractions of treated sera were directly
coated onto ELISA plates overnight at 4°C, which was followed by detection with
HRP-conjugated goat anti-rabbit IgG and reading the absorbance at 450 nm.
RESULTS
Expression and immunoprecipitation analysis of gp120
variant proteins. We have shown previously that although the
YU2 375S/W protein was poorly recognized by several non-
neutralizing CD4BS antibodies, recognition by the potent and
broadly neutralizing CD4BS antibody b12 was also compro-
mised (47). Additionally, attempts to deglycosylate the HX
core S375W protein for structural analysis decreased solubility
to such an extent that crystallographic screening was not pos-
FIG. 1. Immunoprecipitation and ELISA analysis of WT and mu-
tant (T257SS375W) variants of core and gp120 proteins to charac-
terize 17b binding in the presence or absence of sCD4. (A) Immuno-
precipitation and gel analysis. Supernatants from transfection cultures
of envelope glycoproteins were incubated with 17b monoclonal anti-
body and protein A-agarose beads with or without prior incubation
with sCD4. The immunoprecipitated proteins were analyzed by SDS-
PAGE and visualized with Coomassie blue staining. Lane 1, unmodi-
fied core without sCD4; lane 2, unmodified core with sCD4; lane 3,
mutant core without sCD4; lane 4, mutant core with sCD4; lane 5, WT
gp120 without sCD4; lane 6, WT gp120 with sCD4; lane 7, mutant
gp120 without sCD4; lane 8, mutant gp120 with sCD4. Migration of
core proteins (open arrow) and gp120 monomers (solid arrow) is
indicated. (B) ELISA. Equal amounts of affinity-purified unmodified
and mutant proteins were coated onto ELISA plates in duplicates and
reacted with fivefold serial dilutions of 17b antibody in the presence
(solid symbols) or absence (open symbols) of 20 g/ml of sCD4. 17b
binding to various Envs was detected by reacting the wells with anti-
human IgG conjugated to peroxidase. Upper left (circles), WT core;
lower left (diamonds), mutant core; upper right (squares), WT gp120;
lower right (triangles), mutant gp120. Margins of error from duplicate
reactions were negligible in all cases.
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sible (T. Zhou et al., personal communication). The decreased
solubility was attributed to a potential steric clash of the bulky
tryptophan 375 side chain within the Phe43 cavity. Therefore,
we screened a set of second-site mutations of the YU2 375S/W
protein designed to alleviate this potential clash and to gener-
ate an antigenically and biochemically better-behaved mole-
cule stabilized in the CD4 state. One subset of mutations was
modeled to relieve a potential clash in the cavity or to enhance
hydrophobic interactions of the bridging sheet subdomain with
other elements of gp120 and were based upon the crystal
structure. A second subset was selected from mutations stud-
ied previously that reduced CD4BS antibody recognition while
maintaining CD4 binding or enhanced binding to 17b (or to
CCR5) (40, 41, 42). Selected properties of the double muta-
tions are listed in Table 1. Analysis of the panel of eight double
mutations suggested that the combination of T257S and
S375W had the best profile based upon CD4-independent rec-
ognition by 17b, binding to CCR5 in the absence of CD4, and
relative CD4 recognition (Table 1 and data not shown). In
addition, HX core proteins containing the cavity mutations at
positions 257 and 375 expressed well and showed increased
resistance to enzymatic deglycosylation as well as enhanced
solubility following deglycosylation (Zhou et al., personal com-
munication). To test the impact of the cavity-altering muta-
tions eventually in immunogenicity, we introduced these mu-
tations into plasmid DNA sequences encoding envelope
glycoproteins derived from the neutralization-resistant primary
isolate YU2. We focused on further analysis of the structurally
defined YU2 core gp120 in presence of these mutations. For
biological relevance and eventually immunogenicity, we in-
cluded the analysis of the cavity-altering mutations in the con-
text of full-length monomeric gp120 and in the context of the
recently described soluble gp120 trimeric spike mimetics (32).
To confirm the structural integrity of the secreted mono-
meric and trimeric variants, we analyzed the recognition of
proteins in tissue culture cell supernatants by immunoprecipi-
tation with selected antibodies. Consistent with previous ob-
servations (41, 47), full-length gp120 and the full-length
T257S-plus-S375W gp120 proteins were recognized well by the
CD4-induced (CD4i) antibody 17b and were induced slightly in
the presence of CD4 (Fig. 1, lanes 5 to 8). The same mutations
generated in the trimeric gp120 context had an effect similar to
that seen for gp120 (data not shown).
Unlike full-length gp120, core gp120 proteins bind poorly to
17b. The interaction of gp120 with CD4 induces conforma-
tional changes that allow more efficient 17b recognition of the
core proteins. Therefore, 17b recognition of core proteins in
the presence of CD4 is useful as an indicator of proper folding.
Because 17b and CD4 are recognized by the same gp120 con-
formation as that determined in the ternary structure of the
gp120-CD4-17b complex, we also assessed whether recognition
of the mutant core proteins in the absence of CD4 might
indicate the stabilization of gp120 in the CD4-bound confor-
mation by the cavity-altering mutations. As shown in Fig. 1A,
unmodified core protein was weakly recognized by 17b in the
absence of CD4 (lane 1). As expected, 17b binding was greatly
induced in the presence of CD4 (Fig. 1A, lane 2) and repre-
sents the maximal recognition of the core by 17b. A similar
binding pattern was obtained with the cavity-altered core pro-
tein showing only a weak 17b interaction in the absence of CD4
(Fig. 1A, lane 3), but efficient induction of this interaction by
CD4 achieved maximal 17b binding, which is equivalent to that
of the unmodified protein (lane 4). These results indicated that
although the mutant proteins were properly folded, the cavity
mutations by themselves did not completely stabilize core pro-
tein in the CD4-bound conformation (Fig. 1A, lanes 3 and 4).
Similar patterns of 17b binding in the presence and absence of
CD4 were observed by ELISA (Fig. 1B) using affinity-purified
proteins as described below.
Purification and binding analysis of the gp120 glycopro-
teins. The gp120 glycoproteins were purified over affinity col-
umns and analyzed by gel electrophoresis. The migration of
WT and mutant proteins under reducing condition is shown in
Fig. 2A. Under these conditions, monomeric (Fig. 2A, lanes 3
and 4) and trimeric (lanes 5, 6, and 7) gp120 proteins exhibited
similar mobilities, while core proteins were observed as a
faster-migrating species. Differences in molecular weight be-
tween monomeric gp120 and the trimeric gp120-GCN4 vari-
ants were apparent by blue native gel analysis (Fig. 2B). Puri-
fication of proteins possessing the GCN4 trimerization motif
by affinity chromatography revealed that the preparation con-
tained some higher-molecular-weight species as shown in lane
4 of Fig. 2B. Homogeneous trimers were then separated from
the higher-molecular-weight species by size exclusion chroma-
tography (Fig. 2C). For the mutant trimers, gel filtration-pu-
rified trimer fractions were analyzed and purity was confirmed
by blue native gels (Fig. 2B, lane 5) and by gel filtration chro-
matography (Fig. 2D). A similar purification of WT gp120-
GCN4 trimer proteins was described previously (32).
To further characterize the proteins, we performed ELISA
analysis with selected conformational ligands directed against the
CD4 binding site. As described above, the original purpose of
introducing S375W and T257S mutations was twofold: to enhance
the preformation of the gp120 structure that is induced by CD4
binding and to eliminate recognition by CD4BS antibodies.
Therefore, we tested the recognition of the potently neutralizing
CD4BS antibody b12 and two nonneutralizing CD4BS antibod-
ies, F105 and b6. Upon gp120 binding, the nonneutralizing
CD4BS antibodies induce a conformational change to the enve-
lope glycoprotein distinct from that induced by CD4 (47). We
have hypothesized that the decreased binding of the CD4BS an-
tibodies as the result of filling the cavity in a manner that favors
the CD4-bound conformation occurs as a consequence of induc-
ing a gp120 conformation that is incompatible with CD4BS anti-
body recognition. However, since the neutralizing CD4BS anti-
body b12 induces limited, if any, conformational changes to bind
gp120 (21, 47), we hypothesized that the stabilization of gp120 in
the CD4-bound conformation might have less effect on b12 rec-
ognition. In terms of immunogen design, it would be desirable to
retain both the b12 epitope and the CD4 binding site in a candi-
date immunogen engineered to elicit broadly neutralizing anti-
bodies against this region in primary isolates. To test the effects of
the mutations, we performed ELISA studies to determine the
effect of double mutations on the binding of three CD4BS mono-
clonal antibodies to envelope proteins. As described in Mate-
rials and Methods, WT and mutant affinity-purified proteins
were added at equivalent concentrations to lectin-coated
ELISA plates, incubated with fivefold-serially-diluted con-
centrations of the three CD4BS antibodies, and then re-
acted with HRP-conjugated anti-human IgG for colorimet-
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ric detection (Fig. 3). Although by immunoprecipitation, the
single S375W mutation adversely affected b12 recognition,
as shown in Fig. 3, b12 binding to the cavity-filled core pro-
teins was roughly equivalent to unmodified core recognition. In
the context of full-length monomeric gp120, b12 recognition of
proteins possessing the cavity-filling mutations was detected
but was slightly less efficient than that of WT gp120 (Fig. 3).
Importantly, the gp120-GCN4 CD4-state double mutant pro-
teins retained a level of b12 binding equivalent to that of the
WT trimers (Fig. 3). In contrast, all mutant proteins lost the
capacity to be recognized by the nonneutralizing CD4BS anti-
body F105 (Fig. 3, middle panel), consistent with our previous
analysis of the single cavity-altering mutant (47). However, the
double cavity-altering mutations did not eliminate recognition
by all types of nonneutralizing CD4BS antibodies, as the
weakly neutralizing CD4BS antibody b6 remained unaffected
by the cavity mutations in all protein contexts (Fig. 3, bottom
panel). Thereby, binding levels observed with b6, along with
HIV Ig (not shown), served as an internal control for protein
equivalence in the assay.
Because b12 recognition of the T257S375W double mutant
proteins was relatively efficient in this analysis, and because the
poor recognition of the S375W single mutant was determined
previously only by immunoprecipitation, we compared the rela-
tive recognition of b12 to the WT, the single mutant, and the
double mutant gp120 monomers by ELISA. As seen in Fig. 3B,
the single mutant is substantially less well recognized by b12 than
is WT gp120. However, the monomeric double mutant gp120 is
slightly more efficiently recognized by b12 than the single mutant
protein at position 375 (Fig. 3B). In the trimeric gp120 context,
the double mutant protein is recognized by b12 equivalently to
unmodified gp120-GCN4 glycoproteins.
Effect of the cavity mutations on viral entry and sensitivity
to the neutralizing antibody b12. Previously, we observed that
the S375W mutation in YU2 Env decreased entry of the
pseudotyped virus (47). Since the introduction of a second
cavity mutation, T257S, enhanced both protein solubility
(Zhou et al., personal communication) and b12 recognition of
the double mutant protein relative to the single mutant gp120
monomer at position 375 (Fig. 3), we then asked if the intro-
duction of the mutation at position 257 into full-length Env
would impact viral entry or b12 neutralization. As can be seen
in Fig. 4A, when we normalized entry to the quantity of p24 in
a given volume of the viral stock, the presence of the mutation
at position 257 enhanced entry relative to the single mutant
envelope glycoprotein at position 375. We sought to determine
if any correlation of enhanced b12 recognition of the double
mutant monomer could be observed in the context of b12-
meditated viral neutralization. Viruses pseudotyped with the
YU2 envelope glycoproteins harboring either only the S375W
mutation or a combination of S375W and T257S mutations
were assessed for entry in the presence of serial dilutions of the
b12 antibody. The b12 IC50 values showed that viruses harbor-
ing the S375W single mutation were approximately threefold
less sensitive to antibody-mediated neutralization than viruses
possessing the double mutations at positions 257 and 375 (Fig.
4B). HIV IgG and the 2F5 antibody were used as comparative
controls in the neutralization assay. The trend of increased
neutralization sensitivity of double mutant viruses correlates
with increased b12 recognition of gp120 proteins containing
the double cavity-filling mutations compared to gp120 glyco-
proteins possessing only the single S375W mutation as deter-
mined by ELISA analysis (Fig. 3B).
FIG. 2. Reducing SDS-PAGE, blue native gels, and gel filtration profiles of WT and mutant (S375ST257S) YU2 envelope proteins.
(A) Reducing SDS-PAGE of purified envelope glycoproteins. Lane 1, unmodified core; lane 2, mutant core; lane 3, WT gp120; lane 4, mutant
gp120; lane 5, WT gp120 trimer purified by gel filtration; lane 6, mutant gp120 trimer before gel filtration; lane 7, mutant gp120 trimer after gel
filtration. Molecular weight markers (in thousands) are shown on the left. (B) Blue native gel. Lane 1, WT gp120 monomer; lane 2, mutant gp120
monomer; lane 3, WT trimer purified by gel filtration; lane 4, mutant trimer before gel filtration; lane 5, mutant trimer after gel filtration. Molecular
weight markers (in thousands) are indicated on the left. (C) Gel filtration profile of the affinity-purified mutant trimer. (D) Gel filtration profile
of the purified mutant trimeric fraction.
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Thermodynamic analysis of ligand interactions of mutant
envelope glycoproteins. Unmodified proteins and cavity-filled
proteins possessing the replacements at positions 257 and 375
were assayed by ITC to determine if either CD4 affinity or
changes in entropy induced by CD4 were altered in the mutant
glycoproteins. Figure 5 shows the titration profiles for interac-
tion of the WT (left panel) and T257SS375W mutant (right
panel) core proteins with CD4. As mentioned in Materials and
FIG. 3. Antigenicity of WT and mutant glycoproteins. (A) Binding to three CD4 binding-site antibodies was measured by ELISA analysis of
the following proteins: WT proteins (open symbols) and T257SS375W mutant proteins (closed symbols). Top panel, binding to b12; middle panel,
binding to F105; bottom panel, binding to b6. (B) Effect of a second-site mutation (T257S) on b12 recognition. Top panel, comparison of binding
to b12 by WT gp120 (open square), S375W single mutant gp120 (cross), and T257SS375W double mutant gp120 (closed square); bottom panel,
binding to HIV IgG was used as an internal control for protein concentration. Margins of error from duplicate reactions were negligible in all cases.
FIG. 4. Entry and b12 neutralization of pseudotyped WT and mutant HIV-1. (A) Entry of HIV-1 pseudotyped with WT, the S375W single
mutant, and the T257SS375W double mutant YU2 Env. Percent relative entries compared to WT virus are indicated in the graph. The average
values of four replicates from one representative experiment have been plotted. y-axis error bars indicate standard deviations of the replicate
values. (B) Neutralization IC50 values of the three viruses with selected antibodies are shown.
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Methods, the values for enthalpy (H), entropy (S), and the
association constant (Ka) were obtained by fitting the titration
data to a nonlinear least-squares analysis. The dissociation
constant of CD4 binding to each protein variant was obtained
from the inverse of Ka values. The change in enthalpy upon the
binding of CD4 to unmodified core protein (50 kcal/mol) was
close to that observed for the mutant core protein (49 kcal/
mol). Unexpectedly, in the core context, the two cavity-filling
changes greatly increased the affinity for CD4 (1 nM) com-
pared to that for the WT core protein (29 nM). Similar mea-
surements were performed for WT and double mutant pro-
teins in the context of the gp120 monomer as well as in the
context of gp120-GCN4 trimers. Table 2 summarizes the en-
thalpies, entropies, and affinities of these proteins for CD4
binding. The overall enthalpy is higher for full-length gp120
proteins than for the core, both as monomers and as trimers,
consistent with the fact that these proteins contain more resi-
dues that are capable of rearrangement and bond formation
than does the core. Similar to the core proteins, full-length
mutant gp120 showed increased affinity for CD4 binding,
changing from 42 nM for the WT protein to 3 nM for the
mutant protein. Improved CD4 affinity was also observed for
the trimeric mutant, increasing from 58 nM for the WT gp120-
GCN4 trimer to 14 nM for the cavity-filled trimer. This in-
creased affinity was associated with a corresponding decrease
in entropy in all cases, but the degree of stabilization when the
WT was compared to the T257SS375W versions differed
depending upon the protein context. In the core context, sta-
bilization impacted by the cavity-altering mutations was mini-
mal, approximately 8% relative to unmodified core. As mono-
meric gp120, the mutations at positions 257 and 375 reduced
entropy by 25%, and as trimeric gp120, the mutations reduced
entropy by approximately 40% (see theTS values in Table
2). These values reflect increased bond formation on the more
complete gp120 molecules and also indicate that the protein
context may be an important consideration for designing the
most stabilized protein immunogen. We conclude that the
gp120-GCN4 cavity-altered trimeric glycoproteins are partially
FIG. 5. Isothermal titration calorimetry analyses of unmodified and mutant (T257SS375W) YU2 core proteins. ITC experiments representing
the interactions of sCD4 with unmodified (A) and mutant (B) core proteins at 37°C are shown. The top panels represent the raw data as power
versus time. The area under each spike is proportional to the heat produced for each injection. The bottom panels represent integrated areas per
mole of injected ligand (sCD4) as a function of the molar ratio. The solid line represents the best nonlinear fit to the experimental data. (A) H 
50 kcal/mol; Kd  29 nM. (B) H  49 kcal/mol; Kd  1 nM.
TABLE 2. Thermodynamic values of YU2 gp120 variants and sCD4 interactions at 37°C measured by ITC
Protein G (kcal/mol) H (kcal/mol) TS (kcal/mol) Kd (nM) TS (kcal/mol)a
WT core 10.7 	 0.04 49.6 	 2.48 38.9 	 2.48 29
Stabilized core 12.7 	 0.12 48.8 	 2.45 36.0 	 2.45 1 2.9
WT gp120 10.5 	 0.05 68.8 	 3.46 58.3 	 3.46 42
Stabilized gp120 12.0 	 0.09 56.1 	 2.82 44.0 	 2.82 3 14.0
WT trimer 10.3 	 0.06 64.2 	 3.27 53.9 	 3.27 58
Stabilized trimer 11.1 	 0.08 44.5 	 2.25 33.4 	 2.25 14 20.4
a The TS values were calculated by subtracting the TS value of each mutant from that of its unmodified counterpart.
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stabilized in the CD4-bound state, as previously demonstrated
for monomeric gp120 possessing the single S/W mutation at
position 375 (47). These observations supported a rationale to
assess the stabilized double mutant proteins for immunogenic-
ity analysis.
Comparative immunogenicity of the gp120 variants in
rabbits. In this study, gp120-GCN4 double mutant proteins
displayed low nanomolar binding to CD4, exhibited b12 rec-
ognition equivalent to that of WT gp120, and demonstrated
the largest change in entropy upon CD4 binding compared to
those of other mutant variants as determined by ITC. There-
fore, we selected this CD4-state mimetic as our best candidate
to assess the impact of the cavity-altering mutations on immu-
nogenicity. Assessments of the antibody responses elicited in
rabbits by affinity-purified WT gp120 (four animals), WT
gp120-GCN4 (four animals), and T257SS375W gp120-GCN4
proteins (seven animals) were performed at two doses: at the
25-g dose used in a previous study (24) and at a higher dose
of 125 g of protein to determine if this quantity of protein
would elicit more potent and broad responses. All proteins
were emulsified in Ribi adjuvant and inoculated at 4-week
intervals as described in Materials and Methods. Test bleeds
were collected 10 days following each inoculation, and the
isolated sera were subjected to ELISA and HIV-1 neutraliza-
tion assays. Preimmune bleeds were analyzed similarly, and
two rabbits inoculated with BSA in adjuvant served as addi-
tional negative controls. We also included viruses pseudotyped
with murine leukemia virus Env to confirm that the neutral-
ization was specific for HIV Env.
The sera from animals inoculated with both low and high
doses of protein were collected and tested for binding activity
to WT YU2 gp120 protein by ELISA; the results are summa-
rized in Table 3. All of the animals inoculated with the gp120
variants achieved peak titers of anti-gp120 IgG after two to
three inoculations, with the endpoint titers ranging from 2.5 
104 to 6.25  105. Sera from the low-dose-inoculated animals
were tested after three inoculations only and had roughly the
same titer as the sera from high-dose-inoculated animals. Sera
from BSA-immunized rabbits had no detectable titer for
gp120-reactive antibodies (data not shown).
Next, we examined the breadth of HIV neutralization elic-
ited by each of the immunogens after three inoculations for the
both low-dose- and high-dose-inoculated animals. As seen in
Fig. 6, sera derived from animals inoculated with the higher
dose of protein were much more potent at neutralizing a panel
of viruses than sera from those inoculated at the lower dose.
Therefore, we performed another inoculation of the animals
receiving the high dose only.
Even though there were not large differences in the
ELISA titers, the sera elicited by either WT or partially
stabilized proteins following the fourth inoculation dis-
played more potent neutralization than the sera isolated
following the third inoculation (Fig. 6). In general, the
breadth of neutralization improved after four inoculations,
with IC50 values greater than 10 observable in most sera for
seven of the nine primary clade B isolates that were tested.
Due to the small number of animals per group, the ability to
perform statistical analysis was limited. However, by com-
bining all immunogens against all neutralized viruses, a sta-
tistically significant difference between the IC50 values after
three inoculations compared to those following four inocu-
lations was observed by the evaluation of the arithmetic
means by an unpaired t test (P  0.003). By inspection and
statistical analysis of the IC50 neutralization values following
four inoculations, there was no apparent advantage in YU2
homologous neutralization elicited by WT trimeric gp120
glycoproteins compared to that elicited by WT monomeric
gp120 proteins (Fig. 6). Therefore, we combined the IC50
TABLE 3. Endpoint titers of sera from rabbits immunized at low and high doses of glycoproteins as determined by gp120 ELISAa
Immunogen
Inoculation
Low dose High dose
Animal Endpoint titer (3rd) Animal
Endpoint titer
2nd 3rd 4th
WT monomer A1  3   
A2  4   
A3  5   
6   
WT trimer B1  7   
B2  8 NDb  
B3  9   
10   
Stabilized trimer C1  11   
C2  12   
C3  13   
14   
15   
16   
17   
a Endpoint ELISA titers are defined as the last reciprocal serum dilution at which the optical density signal was greater than twofold over the signal detected with
the preimmune sera. Symbols for the endpoint titers are as follows: , 2.5  104; , 1.25  105; , 6.25  105.
b ND, not determined.
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values for sera elicited by either WT monomeric or WT
trimeric gp120 and performed a limited statistical analysis.
In contrast to WT gp120-elicited sera, the sera elicited by
the T257SS375W-stabilized trimers displayed much more
potent homologous neutralization in several individual ani-
mals (Fig. 6). A comparison of the arithmetic mean IC50
neutralization values between the two groups is shown in
Table 4, and the difference in the arithmetic means for YU2
neutralization was just within the range of statistical signif-
icance.
For heterologous neutralization, the stabilized trimers elic-
ited responses against strains BaL, SF162, and SS1196 that by
inspection appeared more potent than those elicited by the
FIG. 6. IC50 neutralization values of different groups of immunized rabbit sera tested against a panel of HIV-1 isolates. Low-dose values were
obtained with sera collected after three inoculations (post-3), and high-dose values were obtained with sera collected after three inoculations
(post-3) as well as after four inoculations (post-4). IC50 values between 100 and 249 are coded in yellow, and those exceeding 250 are highlighted
in red. Virus pseudotyped with murine leukemia virus (MuLV) was used as a negative control for specificity.
TABLE 4. Mean IC50 neutralization values of WT proteins
compared to those of stabilized trimers
Virus
Mean IC50
P valuecWT gp120a
(n  8)b
Stabilized trimer
(n  7)
YU2 121 	 64 983 	 421 0.0494
BaL 37 	 15.3 269 	 100 0.0287
SF162 142 	 51 364 	 91.65 0.0468
SS1196 151 	 60 755.3 	 400.2 0.1337
89.6 32 	 25 80 	 36.4 0.2798
a IC50 values obtained with WT gp120 monomer and WT gp120 trimer were
combined for the analysis.
b n refers to the number of samples (IC50 values) considered for analysis.
c By unpaired t test. A P value of 
0.05 was considered to be significant.
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WT proteins. Statistical significance of these differences was
observed only for BaL and SF162 neutralization by comparing
the arithmetic means of WT gp120-elicited responses to those
elicited by the stable trimers (Table 4), and a trend was ob-
served for SS1196. For strains ADA and 6535, both by inspec-
tion and by statistical analysis, there was no difference in the
IC50 values elicited by WT proteins compared to the stabilized
trimers. For the resistant viruses JR-FL and TRJO.58, no con-
sistent neutralization was observed, indicating the limits of the
neutralization breadth or potency elicited in this study. We did
inoculate selected animals two additional times with immuno-
gen, but we observed neither a consistent pattern of enhanced
neutralization nor any increase in ELISA titers with the addi-
tional boosts.
To confirm that the neutralization was mediated by IgG, we
treated selected sera with protein A-Sepharose beads and
demonstrated that all YU2- and SF162-neutralizing activity
could be depleted from these sera by the beads (data not
shown). We were also able to elute a substantial fraction of
the neutralizing activity from the protein A beads following
treatment with acidic buffer and immediate neutralization of
the eluates (data not shown). Analysis of the eluates by
reducing SDS-PAGE confirmed the presence of bands con-
sistent with the heavy and light chains of purified IgG (data
not shown).
In summary, using an Env-pseudotyped HIV neutralization
assay, we have shown that at high protein doses, monomeric
gp120 elicits relatively broad neutralizing activity and that the
cavity-altered, CD4-state gp120 trimers elicit neutralizing an-
tibodies that are slightly more potent than those elicited by the
WT monomers and trimers.
Mapping binding and neutralization specificity. Several as-
says were performed in attempts to identify the subsets of
either the binding or neutralizing specificities present in the
gp120-elicited antisera. In a recent immunogenicity study using
guinea pigs, we observed that most of the homologous neu-
tralization elicited by the YU2 monomeric gp120 in the adju-
vant AS01b mapped to a single 15-amino-acid region of the V1
loop of gp120 (24). We performed similar peptide inhibition
studies of selected antisera elicited in the rabbits by the high-
dose YU2 monomers and trimers emulsified in Ribi adjuvant
generated in the current study. Surprisingly, no detectable ho-
mologous neutralization elicited by the YU2 gp120 monomers
used in this study could be inhibited by the V1 peptide
identified in the previous study. Sera displaying the highest
titers were analyzed in this manner, two for monomeric
gp120 (samples 3 and 4) as well as two antisera elicited by
the WT gp120 trimers (samples 7 and 8) and all sera elicited
by the stabilized trimers with the exception of sample 31.
Additionally, neutralization of YU2 was not V3 mediated,
as a YU2 V3 peptide was unable to significantly inhibit the
neutralization of selected sera (samples 3, 10, 11, 32, and
33). A minor fraction of neutralizing activity against BaL
could be inhibited by the V3 peptide for selected sera (sam-
ples 7, 8, 11, 12, 15, and 17) (not shown), and no V3-directed
neutralization of ADA was detected (samples 3, 7, 8, 12, 15,
and 16).
Because the CD4-state immunogens might elicit a repertoire
of antibodies against the CD4 binding region different from
that of WT immunogens, we developed novel assays to deter-
mine if we could observe differences regarding the inhibition of
CD4 binding to gp120 or, alternatively, direct binding of anti-
sera to selected gp120 core variants. Because a previous report
described cross-competition effects by monoclonal antibodies
that do not map to the CD4 binding region (28), we used YU2
core gp120 as the binding target to eliminate cross-competition
from antibodies in the sera that would not have specificity for
the CD4 binding region as much as possible (5). In addition,
since the gp120 core protein has a deletion of the major vari-
able loops and residues in the N and C termini, a large fraction
of the native binding surface is accounted for by the CD4
binding site (22, 45, 46). Therefore, we analyzed the ability of
sera elicited by WT proteins to affect the binding of sCD4 to
unmodified YU2 core proteins and compared it to that elicited
by the constrained proteins (Fig. 7). As assay controls, we
preincubated three well-defined antibodies, b12 (CD4BS), 17b
(CD4i), and 2G12 (glycan-dependent outer domain), with core
gp120 on the ELISA plate and then determined their impact
on CD4 binding to the core. As shown in Fig. 7A, the CD4BS
antibody b12 can efficiently block CD4 binding to the gp120
core; this interaction is unaffected by 2G12, and interestingly,
CD4 binding to the core is enhanced by the preaddition of 17b.
Analysis of the experimental sera from the WT protein-immu-
nized rabbits displayed various capacities to inhibit the binding
of CD4 to the gp120 core (Fig. 7B). A markedly different
spectrum of responses was observed when the sera from the
stabilized trimer-immunized rabbits were analyzed similarly
(Fig. 7C). Two of the sera (samples 13 and 16) displayed
slightly reduced CD4 binding, serum sample 15 had little ob-
servable effect, and all other sera (samples 11, 12, 14, and 17)
enhanced CD4 binding to the gp120 core. Since the data sug-
gested that there might be 17b-like antibodies present in the
sera, we performed assays of neutralization of HIV-2 isolate
7312A/V434M by these sera with or without preincubation of
the virus with sCD4 in an assay that is diagnostic for 17b-like
antibodies (12). HIV-1 neutralization in the presence of CD4
was observed only in sera elicited with the CD4-state trimers
(samples 11 to 13) (Fig. 7D). Of these sera, sample 12 showed
a particularly high neutralization response even in the absence
of sCD4. Although it is difficult to compare the effects ob-
served in ELISA to those observed in virus neutralization
assays, it is clear that the stabilized trimer proteins elicited
different types of antibody responses compared to those of the
WT immunogens.
We next performed assays of direct binding of the sera to the
WT YU2 core and to a recently described, cysteine-con-
strained core (Ds12F123) derived from the HXBc2 envelope
glycoprotein that is recognized by CD4 and b12 but not most
other nonneutralizing CD4 binding-site antibodies (49). We
reasoned that if the stabilized trimers elicited CD4 binding-site
antibodies that possessed binding properties similar to those of
CD4 or b12, the sera elicited by these molecules might bind
more efficiently to the cysteine-constrained core. As seen in
Fig. 8, even though the sera elicited by the stabilized trimers
did not recognize the WT YU2 core quite as well as sera
elicited by the unmodified proteins (A and C), several sera did
recognize the cysteine-constrained HXBc2 core proteins more
efficiently (B and D).
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DISCUSSION
The HIV-1 primary receptor-binding site presents a unique
challenge with regard to targeting this surface by neutralizing
antibodies. Due to the extreme variability of many elements of
HIV gp120, this conserved region represents one of the two
functionally conserved surfaces on the protein. Since it was
shown previously that the second conserved gp120 surface, the
chemokine receptor binding site, is not accessible to most
neutralizing antibodies, the CD4 binding site represents the
best surface to target for the generation of broad neutralizing
antibodies. We have attempted a novel means of immunogen
design by stabilizing this site on gp120 by structure-guided
mutagenesis. We have filled the Phe43 cavity, which lies at the
epicenter of the CD4 binding region of gp120, by a selected
pair of mutations within the cavity. In this study, we show that
similar to a single mutation in the Phe43 cavity of gp120, the
paired mutations maintain the increased affinity of gp120 for
CD4 in the core context as well as in full-length and trimeric
gp120 protein contexts. Each of the cavity-filled proteins dem-
onstrates substantial entropic changes upon CD4 ligation con-
sistent with only partial stabilization of these mutants in the
CD4-bound conformation. Importantly, the second-site muta-
tion T257S increases the recognition of the cavity-filled protein
by the potent and broadly neutralizing CD4BS antibody b12.
Since the double mutant core protein remains dependent on
CD4 induction for recognition by 17b (Fig. 1), it is likely that
the cavity-filling mutations do not facilitate the formation of
the bridging sheet structure. Consistent with this, there is a
FIG. 7. Mapping of gp120 and stabilized trimer-elicited sera tested for the capacity to affect sCD4 binding and for the presence of CD4i
antibodies. (A, B, and C) Binding of sCD4 to YU2 core protein was measured by ELISA analysis in the presence of fivefold serial dilutions of the
following reagents: the human anti-gp120 antibodies b12, 2G12, and 17b (A); rabbit antisera obtained after four inoculations with WT gp120
proteins (samples 3 to 7) and WT trimer proteins (samples 8 to 11) (B); and antisera obtained after four inoculations with stabilized gp120 trimer
protein (C). Each data point is an average of duplicate samples with negligible margins of errors that are not visible on the graphs. Two negative
control curves are shown; in A and B, the binding of CD4 in the absence of any inhibitor (marked as no inhibitor) indicates 100% binding; in C,
the average values obtained in the presence of BSA-immunized serum samples 1 and 2 are shown. (D) Neutralization IC50 values of rabbit sera
tested against HIV-2 isolate 7312A/V434M. The pseudovirus was treated with media lacking CD4 (CD4) or containing 0.5 g/ml of sCD4
(CD4) for 1 h prior to adding antisera.
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modest reduction in the entropy change observed during gp120
and CD4 interactions, indicating that the flexibility of gp120
resides in areas other than the CD4 binding region (Table 2).
This observation is consistent with differences between the
structures of unliganded and liganded core gp120 proteins that
suggest that the core inner domain undergoes major structural
rearrangements upon binding to CD4 (7, 22). The impact of
the T257SS375W cavity-filling mutations on the change in
entropy is greater when the mutations are examined in the
full-length gp120 monomer and trimer contexts compared to
the core. This difference is likely due to rearrangements of
residues in the amino and carboxy termini that are not present
in the core, although the variable loop V1, V2, or V3 could
contribute to this difference.
Irrespective of the protein context, a mutation at residue 375
disrupts the binding surface for the CD4BS antibody F105
(47), and the T257SS375W double mutation decreases F105
recognition to an undetectable level. However, the two cavity-
filling mutations had no effect on the binding of another
CD4BS antibody, b6, and a minimal reduction of the binding
of the neutralizing CD4BS antibody b12 (Fig. 3). The finding
that b6 binding is not affected is consistent with the mutagenic
analysis of b6 and b12, demonstrating that the binding require-
ments of the nonneutralizing and neutralizing CD4BS antibod-
ies are remarkably similar (33). The data are consistent with
the model of conformational masking, which suggests that
although CD4 and most CD4BS antibodies bind to a similar
region on gp120, they recognize distinct conformations that
are incompatible with mutual recognition (47). Since b12
does not induce appreciable conformational changes in
gp120 upon binding, it is possible that b12 can recognize the
CD4-bound conformation to a certain degree, and the cross-
competition observed between these two ligands is predom-
inantly steric (28).
By ELISA, we show that the S375W single mutation de-
creases gp120 recognition by b12, consistent with data from
previous studies. However, for the purposes of immunogen
design, we would like to maintain the b12 binding site to permit
the elicitation of b12-like antibodies by our candidate immu-
nogens. Therefore, it is significant that the second mutation in
the Phe43 cavity at position 257 permits more efficient b12
recognition. The presence of the b12 binding site seems to be
a likely requirement for any immunogen that might re-elicit a
b12-like antibody. Consistent with the binding analysis, YU2
pseudoviruses harboring the double mutations in Env enter
cells more efficiently than those possessing the single mutation.
The double mutant viruses also become more sensitive to b12-
mediated neutralization than the S375W single mutant.
The double mutant gp120 trimers were tested as immuno-
gens compared to WT gp120 monomer and trimer proteins.
Used at higher dosages than those used in previous studies
(24), the gp120 monomer itself elicited neutralizing responses
against a panel of clade B viruses. Of particular interest was the
neutralization of the primary strain ADA (Fig. 5). It is possible
that affinity selection and the relatively high functional activity
of the YU2 gp120 used in this study contributed to the rela-
tively potent neutralization elicited by the monomer at the
higher dose of 125 g. We have observed that gp120 proteins
from tissue culture supernatants purified by antibody affinity
chromatography, compared to the purification of the same
protein from supernatants by lectin affinity chromatography,
display up to threefold-more purified gp120 molecules capable
of binding CD4, as determined by ITC (not shown). Such
differences in gp120 “functional activity,” defined by the ca-
pacity to interact with CD4, may be an important but undera-
ppreciated variable in immunogenicity experiments involving
gp120 expressed from DNA or via viral vectors in vivo or in
vitro followed by lectin affinity purification only.
Trimerization of full-length gp120 did not improve the po-
tency or breadth of the neutralizing response. However, the
cavity-filled trimers did elicit more potent neutralizing re-
sponses against many of the viruses tested, as can be seen by an
inspection of Fig. 6. A minimal, if any, increase in the breadth
of neutralization was elicited by the partially stabilized trimers.
These data indicate that in and of themselves, the cavity-filling
mutations examined in the contexts here are not sufficient to
increase neutralization breadth.
As an attempt to map the neutralizing activity elicited by the
selected immunogens, we performed assays that we have used
previously, namely, assays of neutralization competition by
variable loop peptides (24), assays to identify CD4i antibodies
(12), and novel cross-competition assays to determine the ef-
fects of antibodies on the binding of sCD4 to gp120. Recently,
FIG. 8. Binding of WT gp120 and stabilized trimer-elicited sera to
unmodified YU2 core and cysteine-constrained HXBc2 core proteins
detected by ELISA. (A and C) Binding to YU2 core proteins by
antisera elicited by WT gp120 proteins (A) and sera elicited by the
stabilized trimers (C). (B and D) Binding to the cysteine-constrained
HXBc2 core protein Ds12F123 by antisera elicited by WT gp120 pro-
teins (B) and sera elicited by the stabilized trimers (D). Prebleed
antisera and antisera from rabbits inoculated with BSA are included as
negative controls.
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we reported that in guinea pigs, monomeric YU2 gp120 iden-
tical to the protein used in the current study, emulsified in the
GlaxoSmithKline adjuvant AS01b, elicited a predominant V1-
specific homologous neutralizing response. Surprisingly, in the
current study, we did not observe such a focused neutralizing
response elicited by the YU2 gp120. We can attribute the
discrepancy only to differences in the animal species, adjuvant,
and dosages used in the two studies. Little V3-directed neu-
tralizing activity was detected, in agreement with our previous
analysis. We attempted to determine if there was evidence of
increased levels of antibodies directed against the gp120 CD4
binding site, since the immunologic objective desired by stabi-
lizing the gp120 CD4 state is to elicit, in essence, “CD4-like”
antibodies. Few assays are ideally suited to identify such anti-
bodies, but by the best assay currently available, we analyzed
the ability of the sera elicited by the selected immunogens to
competitively inhibit the binding of sCD4 to core gp120. We
chose core gp120 because we showed previously that fewer
cross-competition effects are manifest on core gp120 devoid of
the variable loops than on full-length gp120 (5). Somewhat
surprisingly, we could detect some CD4-blocking antibodies
elicited by WT gp120, in agreement with a previous study (37).
However, in some sera elicited by the CD4-stabilized immu-
nogens, we detected antibodies that were more consistent with
the CD4i antibody class both by binding analysis and by neu-
tralization of a modified HIV-2 virus capable of detecting
CD4i-type antibodies (Fig. 7). This does not mean that the
CD4-state immunogens did not induce CD4-blocking antibod-
ies, since their presence could be masked by the CD4i class.
The results clearly demonstrate that the stabilized immuno-
gens do elicit at least one subset of antibodies different from
the unmodified immunogens. We observed differences in the
antisera elicited by WT proteins compared to those elicited by
the stabilized trimers in terms of recognition of the recently
described cysteine-constrained HXBc2 core proteins (49).
These differences might be due to the slightly more efficient
elicitation of CD4BS or CD4i antibodies by the CD4-state
trimers. Such differences, although not fully defined, likely
contribute to the slightly more potent neutralizing antibodies
elicited by the stabilized trimeric proteins.
Since we have recently reported that gp140 trimers do elicit
enhanced neutralization breadth, it is possible that these par-
tially stabilizing mutations, in concert with other modifications,
may present a path to enhance the neutralizing responses elic-
ited by the soluble and stable gp140 trimers further (24). In
addition, we plan to stabilize gp120 in the CD4-bound confor-
mation further by altering suitable pairs of amino acids to
cysteine residues, especially pairs that would span the inner
and outer domains of gp120. Towards that goal, a series of
disulfide-stabilized mutants have been generated and will be
evaluated in future immunological studies.
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